Neisseria meningitidis News and Research RSS Feed - Neisseria meningitidis News and Research

FDA approves use of Menactra for booster vaccination against meningococcal disease

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age. [More]
Prevalence of bacterial meningitis drops in the United States

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases. [More]
Scientists shed new light on why teenagers are susceptible to meningitis and septicaemia

Scientists shed new light on why teenagers are susceptible to meningitis and septicaemia

University of York scientists have shed new light on why teenagers and young adults are particularly susceptible to meningitis and septicaemia. [More]
Researchers explain how meningitis-causing bacteria evade body's immune system

Researchers explain how meningitis-causing bacteria evade body's immune system

Every once in a while in the U.S., bacterial meningitis seems to crop up out of nowhere, claiming a young life. [More]
Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. [More]
Global market for meningococcal vaccines expected to grow at CAGR of 14.9% from 2013 to 2019

Global market for meningococcal vaccines expected to grow at CAGR of 14.9% from 2013 to 2019

According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019. [More]
Low dose injections of artificial properdin provides protection against septic diseases in mice

Low dose injections of artificial properdin provides protection against septic diseases in mice

Breakthrough MRC-funded study from University of Leicester shows low dose injections of artificial properdin provides substantial protection against septic diseases in mice [More]
Low dose injections of artificial properdin provide protection against septic diseases

Low dose injections of artificial properdin provide protection against septic diseases

Researchers at the University of Leicester have produced an artificial version of a naturally occurring protein, properdin, which has been found to successfully combat bacterial pneumonia and meningitis when tested in mice. [More]
Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip." [More]
Researchers create an efficient technique to target and repair defective genes

Researchers create an efficient technique to target and repair defective genes

Using human pluripotent stem cells and DNA-cutting protein from meningitis bacteria, researchers from the Morgridge Institute for Research and Northwestern University have created an efficient way to target and repair defective genes. [More]
Researchers discover role of TonB bacterial protein that causes various diseases

Researchers discover role of TonB bacterial protein that causes various diseases

A Kansas State University-led study has discovered the role of a protein in bacteria that cause a wide variety of diseases, including typhoid fever, plague, meningitis and dysentery. The results may lead to new and improved antibiotics for humans and animals. [More]
Common sugar molecule promising target for development of broad-spectrum vaccine

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens. [More]

Neisseria meningitidis causes life threatening meningitis, meningococcal sepsis in humans

"Neisseria meningitidis is an important human pathogen that can cause rapidly progressing, life threatening meningitis and meningococcal sepsis in humans," Professor Jennings said. [More]
CRISPR helps some bacteria evade mammalian immune system

CRISPR helps some bacteria evade mammalian immune system

CRISPR, a system of genes that bacteria use to defend themselves against viruses, has been found to be involved in helping some bacteria evade the mammalian immune system. [More]
Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages. [More]
Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. [More]
New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments are urgently needed for bacterial meningitis, a devastating disease which kills or maims around a fifth of people who contract it, according to medical experts writing in a new Series on bacterial meningitis, published in The Lancet. [More]
FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine]. [More]
FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b. [More]
Routine 4CMenB immunizations effective against meningococcal strains in infants

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA. [More]